REPL Replimune Group, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:35
Jun 30
Jun 30
Premarket movers report shows AeroVironment soaring 30% on strong results, Aevex climbing on a contract win, Block upgraded by Piper Sandler, Concentrix tumbling on a lowered outlook, and Replimune gaining on an analyst upgrade.
11:42
May 29
May 29
The author exited a scalp trade in REPL at $7.2, referencing a prior FDA-related context, without expressing a forward directional view.
LOW
11:37
May 29
May 29
Author re-enters $REPL long, citing a shift in FDA direction after key personnel exits as catalyst for improved regulatory outlook.
MED
15:46
Apr 13
Apr 13
Replimune's drug has strong efficacy and support.
The FDA rejection of Replimune's melanoma drug was unfair because the drug has strong efficacy data with a 34% remission rate and durable responses, it resensitizes patients to anti-PD-1 therapy, and has broad support from oncologists and patient advocacy groups, indicating that the drug should be approved and the company has promising prospects.
HIGH
About REPL Analyst Coverage
Buzzberg tracks REPL (Replimune Group, Inc.) across 3 sources. 2 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (50%). 4 total trade ideas tracked. Latest voices: zerohedge, seedy19tron, Philip Astley-Sparke.